Log in with your email address username.


[Comment] Dupilumab: a potential new treatment for severe asthma

In The Lancet, a phase 2b dose-ranging study of dupilumab, a human anti-interleukin-4 receptor α antibody that inhibits the downstream effects of the type 2 mucosal immunity cytokines, interleukin 4 and interleukin 13, is reported.1 Over 24 weeks, dupilumab was efficacious as an add-on therapy to medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist in patients with uncontrolled persistent asthma, with improvement in baseline forced expiratory volume in 1 s (FEV1), which was the primary endpoint, as well as a reduction in annualised exacerbation rates and improvements in quality of life and asthma control all being more evident when injections were given every 2 weeks compared with every 4 weeks.